0000000000897010

AUTHOR

Gian Paolo Fadini

0000-0002-6510-2097

showing 2 related works from this author

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective …

2018

Introduction DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of real-world studies comparing their effectiveness in routine clinical practice. Methods This was a multicenter retrospective study on diabetes outpatient clinics comparing the effectiveness of DPP4i versus gliclazide extended release. The primary endpoint was change from baseline in HbA1c. Secondary endpoints were changes in fasting plasma glucose, body weight, and systolic blood pressure. Automated software extracted data from the same clinical electronic chart system at all centers. Propensity score matching (PSM) was used to generate comparable coh…

endocrine systemmedicine.medical_specialtyEpidemiologyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyDatabase03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal medicinemedicineClinical endpointDatabase; Epidemiology; Pharmacotherapy; Internal Medicine; Endocrinology Diabetes and MetabolismInternal MedicineOutpatient clinicGliclazideOriginal ResearchGlycemicbusiness.industrynutritional and metabolic diseasesDatabase; Epidemiology; PharmacotherapyRetrospective cohort studymedicine.diseasePharmacotherapyMetforminDiabetes and Metabolismbusinessmedicine.drug
researchProduct

Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study.

2019

Aim: To evaluate the changes in renal endpoints in type 2 diabetes patients treated with dapagliflozin versus other glucose-lowering medications in routine clinical practice. Materials and Methods: DARWIN-T2D was a retrospective study conducted at 46 outpatient diabetes clinics in Italy. An automated software collected data on 17 285 patients who received dapagliflozin, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, or gliclazide, 6751 of whom had a follow-up visit. We analysed changes in albumin excretion rate (AER) and estimated glomerular filtration rate (eGFR). Results: Patients who received dapagliflozin (n = 473) were younger, more obese, and had a poore…

MaleEndocrinology Diabetes and MetabolismType 2 diabetes030204 cardiovascular system & hematologyKidneychemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesRetrospective StudieInterquartile rangeMedicineGliclazideDiabetic NephropathiesDapagliflozinPractice Patterns Physicians'Benzhydryl CompoundAged 80 and overdatabase researchMiddle AgedDiabetes and MetabolismTreatment OutcomeItalyFemaleOriginal Articletype 2 diabetesHumanmedicine.drugGlomerular Filtration Ratemedicine.medical_specialtyGlucosideDrug-Related Side Effects and Adverse ReactionsUrologyRenal function030209 endocrinology & metabolism03 medical and health sciencesDiabetes mellitusantidiabetic drug; dapagliflozin; database research; diabetic nephropathy; type 2 diabetes; Internal Medicine; Endocrinology Diabetes and Metabolism; EndocrinologyInternal MedicineHumansHypoglycemic AgentsBenzhydryl CompoundsAgedRetrospective Studiesantidiabetic drugtype 2 diabeteCreatinineHypoglycemic Agentbusiness.industrydiabetic nephropathyRetrospective cohort studyBiomarkerOriginal Articlesdapagliflozinmedicine.diseasechemistryDiabetes Mellitus Type 2Diabetic NephropathieDrug-Related Side Effects and Adverse ReactionbusinessBiomarkersDiabetes, obesitymetabolism
researchProduct